Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
The ideal anticancer regimen is one that is specific for cancer cells with limited toxicity to normal tissues. Genetically modified, nonpathogenic Salmonella offer a potential way to induce direct tumoricidal activity or to deliver tumoricidal agents to tumors. An attenuated strain of Salmonella typhimurium, called VNP20009, and its derivative TAPET-CD (which expresses Escherichia coli cytosine deaminase) are highly selective for tumor tissue and can deliver therapeutic proteins preferentially to tumors in preclinical models. Both VNP20009 and TAPET-CD have been investigated successfully in Phase 1 clinical trials in cancer patients.
King
Ivan
I
Pharmaceuticals Inc., New Haven, CT, USA.
Itterson
Martina
M
Bermudes
David
D
D000818:Animals; D002876:Chromosomes, Bacterial / Q000235:genetics; D003001:Cloning, Molecular; D043525:Cytosine Deaminase / Q000378:metabolism*; D004926:Escherichia coli / Q000201:enzymology; D005260:Female; D005472:Fluorouracil / Q000493:pharmacokinetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000628:therapy*; D009928:Organ Specificity; D012486:Salmonella typhimurium / Q000235:genetics*; D014018:Tissue Distribution
D043525:Cytosine Deaminase; D005472:Fluorouracil